DOI: 10.1192/j.eurpsy.2026.11180 ISSN: 0924-9338

ChatGPT versus expert psychiatrist in managing mixed mania: a comparative case study

F. Zaouali, I. Anes

Introduction

Artificial intelligence (AI) models, such as ChatGPT, are increasingly explored for clinical decision support in psychiatry. Mixed mania, featuring simultaneous manic and depressive symptoms, poses diagnostic and therapeutic challenges. The reliability of AI recommendations for such complex cases remains largely unknown.

Objectives

To evaluate ChatGPT’s performance in managing mixed mania by comparing its responses to two clinical cases with those of a senior psychiatrist, assessing adherence to current clinical guidelines.

Methods

Two anonymized mixed mania case vignettes were presented to ChatGPT (GPT-4.0) and a senior psychiatrist. Responses were evaluated independently by two psychiatrists for: diagnostic accuracy, appropriateness of pharmacological and non-pharmacological recommendations, and guideline adherence. Discrepancies were resolved by consensus. Performance metrics included agreement with guidelines and concordance between ChatGPT and the human expert.

Results

ChatGPT correctly identified the diagnosis in 1 of 2 cases; the senior psychiatrist achieved 2/2 correct diagnoses. Pharmacological recommendations by ChatGPT partially aligned with guidelines, suggesting first-line mood stabilizers but insufficiently addressing comorbid depressive symptoms. Non-pharmacological advice was general and lacked individualized psychosocial interventions. Overall guideline adherence was 65% for ChatGPT versus 95% for the psychiatrist. Concordance between ChatGPT and the psychiatrist was moderate (Cohen’s kappa = 0.56).

Conclusions

ChatGPT shows partial capability in recognizing and managing mixed mania, with moderate guideline adherence. AI may offer preliminary guidance, but expert psychiatric evaluation remains essential for complex mood disorders. Further AI refinement and training on nuanced psychiatric cases are needed to improve reliability and clinical utility.

Disclosure of Interest

None Declared

More from our Archive